Jing Liu

发表

Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2019, Journal of medicinal chemistry.

Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, International journal of pharmaceutics.

STK16 regulates actin dynamics to control Golgi organization and cell cycle

Qingsong Liu, Xingxing Yang, Wen-chao Wang, 2017, Scientific Reports.

An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.

Qingsong Liu, Xiaofei Liang, Junqing Wang, 2020, Nanomedicine : nanotechnology, biology, and medicine.

A study on the thermochemotherapy effect of nanosized As2O3/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo

Jia Zhang, Dongsheng Zhang, Li Wang, 2011, Nanotechnology.

Production of the monoclonal antibody against Sudan 2 for immunoassay of Sudan dyes in egg.

F. Gao, Jing Liu, Fengli Gao, 2012, Analytical biochemistry.

CircKEAP1 serves as a ceRNA to suppress lung adenocarcinoma progression by activating KEAP1 signal pathway

L. Yao, Da-Wei Sun, Jing Liu, 2020 .

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2017, Journal of medicinal chemistry.

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

N. Gray, Qingsong Liu, W. Hur, 2017, European journal of medicinal chemistry.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Qingsong Liu, Q. Liu, Juan Liu, 2020, Signal Transduction and Targeted Therapy.

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia

Qingsong Liu, E. Weisberg, Xiaofei Liang, 2020, Haematologica.

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities

Qingsong Liu, Hong Wu, Beilei Wang, 2022, MedComm.

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.

Qingsong Liu, X. Liu, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2020, Journal of medicinal chemistry.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes.

Q. Liu, Ao-li Wang, F. Zou, 2022, Journal of medicinal chemistry.

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Qingsong Liu, Zhenquan Hu, Cheng Chen, 2021, European journal of pharmacology.

Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR

Qingsong Liu, Xiaofei Liang, U. Eggert, 2016, PloS one.

Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.

Qingsong Liu, Zhenquan Hu, Q. Liu, 2018, European journal of medicinal chemistry.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Qingsong Liu, C. Yun, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Q. Liu, Juan Liu, Ao-li Wang, 2022, Acta Pharmacologica Sinica.

Effective detection of tyrosinase by Keggin-type polyoxometalate-based electrochemical sensor

Jing Liu, Jiachun Zheng, S. Cai, 2021, Journal of Solid State Electrochemistry.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Hong Wu, C. Niu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.

Q. Liu, Xiaofei Liang, Juan Liu, 2022, European journal of medicinal chemistry.

Highly efficient detection of Tricaine methanesulfonate based on the nanoporous gold electrochemical sensor

Jing Liu, S. Cai, Li Wang, 2021 .

Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2017, European journal of medicinal chemistry.

Natural products as kinase inhibitors.

Qingsong Liu, Jing Liu, Junfeng Wang, 2012, Natural product reports.

Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.

Zhenquan Hu, Q. Liu, Hong Wu, 2018, European journal of medicinal chemistry.

Rapid detection of tyrosinase in shrimp by polyacid-based electrochemical sensors

Jing Liu, Yu-Shan Chen, Xiaoyan Ding, 2022, Tungsten.

Salviachinensines A-F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis.

Qingsong Liu, Zhenquan Hu, S. Cao, 2018, Journal of natural products.

An overview of kinase downregulators and recent advances in discovery approaches

Qingsong Liu, Hai-zhen Wang, Hong Wu, 2021, Signal Transduction and Targeted Therapy.

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Molecular Biomedicine.

Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo

Zhiqiang Gao, Jia Zhang, Dongsheng Zhang, 2011, International journal of nanomedicine.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

W. Ni, J. Griffin, Q. Liu, 2022, Leukemia.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Qingsong Liu, C. Yun, Zhenquan Hu, 2016, Oncotarget.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Jing Liu, Cheng Chen, Wei Wang, 2017, Journal of medicinal chemistry.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Zhenquan Hu, Q. Liu, Hong Wu, 2017, Journal of medicinal chemistry.

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2019, Cancer letters.

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

Qingsong Liu, X. Liu, X. Xiao, 2019, Therapeutic advances in medical oncology.

Brassinosteroids synthesised by CYP85A/A1 but not CYP85A2 function via a BRI1-like receptor but not via BRI1 in Picea abies

Guishuang Li, Guang Wu, Li Wang, 2020, Journal of Experimental Botany.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.

Zhenquan Hu, Q. Liu, Cheng Chen, 2019, Journal of medicinal chemistry.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Q. Liu, Zong-ru Jiang, Cheng Chen, 2020, Acta Pharmacologica Sinica.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Zong-ru Jiang, Cheng Chen, Ao-li Wang, 2020, Acta Pharmacologica Sinica.

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Q. Liu, Hong Wu, Zong-ru Jiang, 2023, Signal Transduction and Targeted Therapy.

Discovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

X. Liu, Zhenquan Hu, Q. Liu, 2019, Journal of medicinal chemistry.

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

Qingsong Liu, Yinsheng Wang, E. Weisberg, 2021, Signal Transduction and Targeted Therapy.

Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.

Qingsong Liu, C. Yun, Zhenquan Hu, 2017, European journal of medicinal chemistry.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.

X. Liu, Zhenquan Hu, Q. Liu, 2020, European journal of medicinal chemistry.

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.

Qingsong Liu, Cheng Chen, Ao-li Wang, 2020, Experimental cell research.

All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.

Qingsong Liu, Zong-ru Jiang, Juan Liu, 2020, Cancer letters.

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

Q. Liu, Hong Wu, Zong-ru Jiang, 2019, Investigational New Drugs.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

Qingsong Liu, Q. Liu, Hong Wu, 2022, Acta Pharmacologica Sinica.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

Clavukoellians A-F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri.

Qingsong Liu, Zhenquan Hu, Jing Liu, 2019, Journal of natural products.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Q. Liu, Hong Wu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Qingsong Liu, Hong Wu, Zong-ru Jiang, 2022, Molecular oncology.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

The Relationship between Cortisol Activity during Cognitive Task and Posttraumatic Stress Symptom Clusters

Kan Zhang, Jianhui Wu, Liang Zhang, 2015, PloS one.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Q. Liu, Zong-ru Jiang, Juan Liu, 2023, European journal of pharmacology.

Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.

Qingsong Liu, Zhenquan Hu, Juan Liu, 2017, Journal of medicinal chemistry.

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

X. Liu, Q. Liu, Zong-ru Jiang, 2019, Acta pharmaceutica Sinica. B.

Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium.

Zhenquan Hu, Q. Liu, Xiaofei Liang, 2019, European journal of medicinal chemistry.

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Using "On/Off" (19)F NMR/Magnetic Resonance Imaging Signals to Sense Tyrosine Kinase/Phosphatase Activity in Vitro and in Cell Lysates.

Gongyu Li, Hongbin Sun, G. Liang, 2016, Analytical chemistry.

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

Qingsong Liu, Yuexiang Wang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

Zhenquan Hu, Q. Liu, Hong Wu, 2019, Cancer biology & therapy.

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

Q. Liu, Chen Hu, F. Zou, 2023, Acta pharmaceutica Sinica. B.

Biocompatibility of Fe 3 O 4 @Au composite magnetic nanoparticles in vitro and in vivo

Jia Zhang, Dongsheng Zhang, Mei Lin, 2011 .

Biocompatibility Study of Mn0.5Zn0.5Fe2O4 Magnetic Nanoparticles

Jia Zhang, Li Wang, Jing Liu, 2011 .

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus

Q. Liu, Chen Hu, F. Zou, 2023, Signal Transduction and Targeted Therapy.

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.

Q. Liu, Chen Hu, F. Zou, 2023, European journal of medicinal chemistry.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.

Q. Liu, Juan Liu, F. Zou, 2023, European journal of medicinal chemistry.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo

Zhiqiang Gao, Jia Zhang, Dongsheng Zhang, 2011, International Journal of Nanomedicine.

Plant steroid hormones synthesised by CYP85A/A1 but not CYP85A2 function through receptors BRI1-like but not BRI1 in Picea abies.

Guishuang Li, Guang Wu, Li Wang, 2020, Journal of experimental botany.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Xiaofei Liang, Zhenquan Hu, Q. Liu, 2018, Journal of medicinal chemistry.

Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.

F. Zou, Qingwang Liu, Li Wang, 2024, Journal of medicinal chemistry.